R&D, Real estate

After revamping R&D in a global shakeup, Bayer prepping new labs for an expansion in cancer research at MIT

At Bayer, Pittsburgh is out, Cambridge, MA is in.

As part of a global shakeup that is costing 12,000 jobs, Bayer recently announced that it will shut down its old US HQ in Pennsylvania, axing hundreds of staffers. And that is happening while R&D is taking a big hit at the German multinational, with 900 researchers getting cut as Bayer completes the troublesome Monsanto acquisition.

But that doesn’t mean they’ve stopped adding research staff in the fields where they plan to grow.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->